

Table S1: Adverse events linked to Androgen Deprivation Therapy (ADT)

<u>Symptoms</u>	N	(%)
General symptoms	9	(9.0)
Asthenia grade ≥ 2	7	(6.9)
Weight gain $\geq 5\%$	2	(1.9)
Locomotor events	17	(16.8)
Arthralgia grade ≥ 2	2	(1.9)
Myositis grade ≥ 2	1	(0.9)
Osteoporotic fracture	4	(3.9)
Cardiovascular events	23	(22.8)
Coronaropathy	6	(5.9)
Cerebrovascular disease	3	(2.9)
Congestive heart failure	4	(3.9)
Phlebitis or pulmonary embolism	2	(1.9)
Carotide stenosis	3	(2.9)
Neurological events	7	(6.9)
Cognitive disorders	7	(6.9)
Biological events	3	(2.9)
Anemia (no cause)	2	(1.9)
Hepatic cytolysis grade ≥ 2	1	(0.9)
Total	44	(43.6)
Stop ADT due to AE	10	(10.0)
Death due to AE	2	(1.9)

AE ; Adverse Events ; ADT : Androgen Deprivation Therapy ; N : Number

Table S2: a) Cardiovascular events in older patients (groups A + B ; N = 101). Univariate analysis.

Variables	OR	CI 95%	p-value
Age (≥82 vs <82 years)	5.57	1.42-21.86	0.014
Intermediate-risk (IR)/ high-risk (HR)	1.49	0.43-5.19	0.528
ADT median duration (≤6 vs >6 months)	1.83	0.52-6.43	0.344
Karnofsky score (≥100% vs <100%)	0.63	0.09-4.24	0.635
Charlson score (≤5 vs >5)	2.40	0.61-9.49	0.212
ACE 27 score (≤1 vs >1)	0.88	0.18-4.17	0.867
Anticoagulant and/or antiaggregant	2.92	0.78-10.92	0.112
Antidiabetes drug	1.25	0.24-6.54	0.792
Antihypertensive drug	1.91	0.48-7.64	0.361
Normalization of testosterone levels	0.82	0.24-2.84	0.752

b) Cardiovascular events in older patients (groups A + B; N = 101). Multivariate analysis.

Variables	OR	CI 95%	p-value
Age (≥82 vs <82 years)	7.15	1.52-33.75	0.013
Charlson score (≤5 vs >5)	1.26	0.24-6.55	0.783
Anticoagulant and/or antiaggregant	3.54	0.67-18.81	0.138

ADT : Androgen Deprivation Therapy ; HR : High-risk, IR : Intermediate-risk; N: Number; **OR** : Odd Ratio ; **CI**: Confidence Interval